Partnering for progress – Reset rheumatoid arthritis

Arthritis Australia is proud to be a key partner in the RESET RA project, which is developing immunotherapy that could revolutionise the treatment for rheumatoid arthritis.

This world-leading research is being led by Professor Ranjeny Thomas AM, a rheumatologist and world-leading researcher at the University of Queensland, Translational Research Institute. Also participating are: Monash University, Macquarie University, Flinders University, University of Sydney, Queensland Health, Kings College London, Newcastle University, and Leiden University Medical Center.

Arthritis Australia is very grateful that the work has been made possible by the Australian Government’s Medical Research Future Fund.

Through this support from the Australian Government, Arthritis Australia and people living with rheumatoid arthritis are central to guiding this ground-breaking Australian research.

What is RESET RA?

This study is exploring a completely new approach to rheumatoid arthritis, providing targeted treatment early to help prevent it from becoming a long-term condition. The treatment is called antigen-specific immune tolerising immunotherapy.

This new approach aims to use targeted immunotherapy to ‘reset’ the immune system, aiming to switch off the cause of inflammation so the arthritis does not return.

Picture Courtesy University of Queensland: Professor Ranjeny Thomas AM

Is this treatment ready for use?

This pioneering treatment is under advanced development and is not yet ready for routine clinical use.

Progress is nevertheless continuing rapidly, supported by the Australian Government, through a Medical Research Future Fund Frontiers Grant. As part of this work, we are understanding more about how rheumatoid arthritis works.

Early stage clinical trials are expected to start in the second half of 2026.

Register to stay informed: 

Name(Required)
Email(Required)
I am interested in(Required)